CD8A and neoplasm: Nanocarriers can enhance cytosolic delivery of TAAs, leading to endosomal escape and processing via proteasome into peptides loaded onto MHC I molecules for the induction of anti-tumor, antigen-specific CD8+ T cell immunity.